Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer shows an updated site revision identifier, with no apparent changes to the study record.SummaryDifference0.1%

- Check9 days agoChange DetectedThe study page displays details for the reslizumab EGPA trial, including its treatment plan, eligibility criteria, outcomes, and contact information. It also shows the study’s recruiting status and record history.SummaryDifference45%

- Check16 days agoChange DetectedThe site footer’s revision label changes from v3.7.2 to v3.8.0; the page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check30 days agoChange DetectedA general NIH banner was added about the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision number changed from v3.7.1 to v3.7.2.SummaryDifference1%

- Check44 days agoChange DetectedThe site revision identifier in the footer changed from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now displays a 403 Forbidden error, blocking access to the record and replacing the previous study details with a standard error page.SummaryDifference17%

Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.